LianBio
is a New Jersey-based biotechnology company that researches and develops paradigm-shifting medicines for the treatment of oncology and cardiovascular disease... Read moreLianBio
is a New Jersey-based biotechnology company that researches and develops paradigm-shifting medicines for the treatment of oncology and cardiovascular disease... Read more
News
Feb 28, 2024
GlobeNewswire
Press Release: LianBio : LianBio Announces Voluntarily Delisting from Nasdaq
Feb 15, 2024
Medthority
LianBio: LianBio to wind down.
Feb 14, 2024
ChinaBio Today
LianBio: LianBio to Shut Down Operations; Will Distribute $528 Million to Shareholders
Dec 27, 2023
Pharmabiz
LianBio: Nanobiotix's partner LianBio inks pact with Janssen to develop and commercialize potential firstinclass radioenhancer NBTXR3 in China and other Asian markets
Dec 02, 2023
ChinaBio Today
LianBio: Week in Review: Tang Capital Offers $465 Million for LianBio Plus 80% of any Licenses/Divestments
Dec 01, 2023
BioSpace
LianBio: LianBio Confirms Receipt of Unsolicited Proposal from Concentra Biosciences
Nov 13, 2023
GlobeNewswire
Press Release: LianBio : LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Oct 31, 2023
Medthority
LianBio: LianBio announces topline results from phase III LIBRA trial of TP 03 in Chinese patients with Demodex blepharitis.
Oct 31, 2023
Global Legal Chronicle
LianBio: LianBio's License Agreement with Bristol Myers Squibb
Oct 25, 2023
ChinaBio Today
LianBio: LianBio Sells China Rights to Cardiovascular Drug for $350 Million to BMS
